Siemens Healthcare Diagnostics, Inc. 2023-09-06 Health serious FDA
Health · FDA · Recall #FDA-Z-1270-2023
Atellica CH Triglycerides (concentrated)-In vitro diagnostic use in the quantitative… Recall
Issued September 6, 2023 · Siemens Healthcare Diagnostics, Inc.
In September 2023, Siemens Healthcare Diagnostics, Inc. recalled the Atellica CH Triglycerides (concentrated)-In vitro diagnostic use in the quantitative…, a serious health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Reagent Carryover from LDL Cholesterol Direct (DLDL), Total Protein II (TP), Triglycerides (Trig), and Triglycerides_2 (Trig_2) Impacting Magnesium (Mg) Results
What you should do
- 1 Stop using Atellica CH Triglycerides (concentrated)-In vitro diagnostic use in the quantitative… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Siemens Healthcare Diagnostics, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Siemens Healthcare Diagnostics, Inc.
- Category
- Health
- Recall date
- September 6, 2023
- Units affected
- Not reported
- Sold at
- Nationwide Foreign: Country Albania Algeria Argentina Australia Austria Bahrain Bangladesh Belgium Brazil Bulgaria Burkina Faso Canada Chile
- Recall number
- FDA-Z-1270-2023
- Made in
- United States
- Issuing agency
- FDA
In context
- Siemens Healthcare Diagnostics, Inc. has 8 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 903rd Health recall we've logged in 2023.